about
Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewRufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trialRevised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009Outcomes in newly diagnosed epilepsy in adolescents and adults: Insights across a generation in Scotland.Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts.Refractory epilepsy: a progressive, intractable but preventable condition?Is refractory epilepsy preventable?Current position of phenobarbital in epilepsy and its future.Road to refractory epilepsy: the Glasgow story.Phenobarbital for the treatment of epilepsy in the 21st century: a critical review.Levetiracetam in refractory epilepsy: a prospective observational study.Emerging drugs for epilepsy.Epilepsy in later life.Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy.Measuring the efficacy of antiepileptic drugs.A case report: retigabine induced oral mucosal dyspigmentation of the hard palate.Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.Medical therapy of epilepsy: when to initiate treatment and when to combine?Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs.Zonisamide as adjunctive therapy for refractory partial seizures.Active control comparisons: the ideal trial design.Outcomes research: clinical trials in the elderly.Refractory epilepsy: mechanisms and solutions.Modern antiepileptic drugs: guidelines and beyond.Combination therapy in epilepsy: when and what to use.Epilepsy: randomised trials and genetic tribulations.Management of a first seizure. Special problems: adults and elderly.Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)Should all patients be told about sudden unexpected death in epilepsy (SUDEP)? Pros and Cons.Selection of antiepileptic drugs in adults.Antiepileptic drug therapy the story so far.Pharmacotherapy of epilepsy: newly approved and developmental agents.Combining antiepileptic drugs--rational polytherapy?Antiepileptic drug therapy: does mechanism of action matter?Adjunctive lacosamide in clinical practice: sodium blockade with a difference?Drug-resistant epilepsy.Newer drugs for focal epilepsy in adults.Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults.Pharmacoresistance.
P50
Q26743786-AC7E636F-C8B8-4556-969B-69CCBC8CE441Q28247222-59B8B4D4-0E95-48C5-8BC5-A0A680B090F6Q28274778-8FA5C23E-8450-4FF2-90A3-344BD8AEB5E1Q30245261-EC0E9035-FB62-4BB8-92AC-BAAB656A9A70Q33447810-A2DA8497-60D0-483C-BAD8-9419D1D343F9Q34123186-C5B5EF7C-A3CA-44AF-982E-B03E7625E610Q34123660-627D0622-38E1-4F22-AE56-29E1B6F66A42Q34315078-1F620D4F-6EDF-47E4-8414-6B4305D6A6A4Q34343111-DE0B3EA0-0294-460D-A6A4-343AFE476DDCQ34343308-83DD0B8B-33D6-4327-BF9E-30D3426BB570Q34383254-9B53123C-02E7-42B9-B0B9-A989DB9F3156Q34688725-54DACA9F-4449-4C48-87B7-0FA311E1BEDEQ35006257-F9D0C015-FDAE-415F-A0D4-D24FECD7A4A8Q35011242-13621290-7A77-4D17-8EF7-83B5D00E830CQ35149566-36D9354A-E042-4554-9C08-FA700F8EE882Q35216352-08C1968B-1B5B-45BF-82DE-8EB16C9E59F4Q35802130-8F0BEDE1-3281-49EB-963B-B7CFF0D2F11DQ36023613-22119B51-79EC-427B-A7B6-22FD4ECA7A09Q36053714-EE888E71-9716-4044-ADE1-82836D7BEE7CQ36319435-8AF89802-31CB-4F6F-9865-E2EEF35A27D1Q36326447-59C0FE9B-539A-493A-BAA4-DE6A03EBCC41Q36353100-DFE237A8-FCCD-4592-9ACB-E5BCF599DBB5Q36368401-30FAF0CA-F19B-4380-B7F0-67D83EC02B40Q36419584-886A4ECA-63B1-4CBD-809D-8ADC683152AAQ36421611-DD01C134-C099-448D-8172-0E13BA29B8C1Q36622991-2CAFD9B9-5C7C-44B8-B9FD-314028241BADQ37037916-2F01548E-40C8-4E02-BA18-0561057D07E6Q37053868-6922EFBC-FC7E-479B-96CB-7B92270D2018Q37242260-41FCD10D-CF0C-4D78-B6EE-13AA593D9C01Q37352162-D1E5C0B0-2715-442D-9E35-289EE22E4F3FQ37620583-52BBD5A4-5C83-492E-9878-7403D287FBC2Q37809292-94265501-0108-42B1-9616-B12E91D516C9Q37831297-2EFA4A13-B6EC-4B6B-92FE-14DD6FAD89D2Q37838580-793B9B86-508B-4E98-B0DD-C6280194C976Q37901704-9E4B147C-A963-4F96-8524-CD8580ECC4C0Q37926255-A205E4C4-B99F-4487-9B3A-97D06F916995Q37928677-280314CB-DC5E-4AB0-AAD1-EF709A01639BQ37979169-05C31ACA-CAEA-4662-8B3A-9F25801E915FQ37982947-62188902-8DA3-43E5-A240-0AFEA4C9ABA2Q38039641-247CA221-16E7-43B7-B44D-7FA7068609F7
P50
description
researcher ORCID ID = 0000-0003-1781-2892
@en
wetenschapper
@nl
name
Martin J Brodie
@ast
Martin J Brodie
@en
Martin J Brodie
@es
Martin J Brodie
@nl
type
label
Martin J Brodie
@ast
Martin J Brodie
@en
Martin J Brodie
@es
Martin J Brodie
@nl
prefLabel
Martin J Brodie
@ast
Martin J Brodie
@en
Martin J Brodie
@es
Martin J Brodie
@nl
P1006
P214
P1006
P214
P31
P496
0000-0003-1781-2892
P735
P7859
viaf-93366747